89bio Q2 EPS $(0.48) Beats $(0.57) Estimate
Portfolio Pulse from Benzinga Newsdesk
89bio (NASDAQ:ETNB) reported a Q2 EPS loss of $(0.48), beating the analyst consensus estimate of $(0.57) by 15.79%. This represents a 7.69% improvement over the $(0.52) loss per share from the same period last year.
August 05, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
89bio reported a Q2 EPS loss of $(0.48), beating the analyst consensus estimate of $(0.57) by 15.79%. This is a positive indicator as it shows a 7.69% improvement over the same period last year.
Beating EPS estimates by a significant margin and showing year-over-year improvement is a positive indicator for the stock. Investors may view this as a sign of better-than-expected financial health and operational efficiency.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100